Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
MWN-AI** Summary
Alterity Therapeutics, a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, announced its upcoming participation in the Bell Potter Healthcare Horizons Summit, scheduled for March 12-13, 2026, in Sorrento, Australia. CEO Dr. David Stamler will engage in a fireside chat titled "Optimising Late-stage Clinical Trials to Increase the Odds," where he will share insights on enhancing clinical trial success rates. Additionally, Dr. Stamler will conduct one-on-one investor meetings during the summit.
The company is particularly focused on Multiple System Atrophy (MSA), a rare and severe neurodegenerative disorder. Alterity's flagship product, ATH434, is set to enter a Phase 3 pivotal trial, following promising results from a randomized, double-blind, placebo-controlled Phase 2 trial, which demonstrated clinically significant efficacy in MSA patients. The company also has reported encouraging data from an open-label Phase 2 trial involving patients with advanced MSA.
Based in both Melbourne, Australia, and San Francisco, California, Alterity is at the forefront of developing innovative therapies aimed at addressing the complex pathology of various neurodegenerative diseases. In addition to its core focus on MSA, Alterity is leveraging a comprehensive drug discovery platform to generate novel, patentable chemical candidates for treating neurological disorders.
As Alterity prepares to scale its clinical efforts, the insights shared at the Bell Potter Summit could bolster investor interest and enhance its strategies for successful trial execution. For more information on Alterity Therapeutics, interested parties can visit their website at www.alteritytherapeutics.com.
MWN-AI** Analysis
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, is poised for significant market activity as it prepares to participate in the Bell Potter Healthcare Horizons Summit on March 12-13, 2026. The involvement of CEO Dr. David Stamler in a key discussion on optimizing late-stage clinical trials underscores the company's commitment to advancing its lead asset, ATH434, aimed at treating Multiple System Atrophy (MSA).
Investors should closely monitor the upcoming pivotal Phase 3 trial for ATH434, which follows promising results from earlier Phase 2 studies demonstrating clinical efficacy. MSA is a rare and rapidly progressive disease, and successful trial outcomes could position Alterity as a leader in this niche market, potentially translating into substantial revenue growth.
The participation in the summit presents an opportunity for Alterity to bolster investor engagement, particularly through 1-on-1 meetings, which may result in increased institutional interest and support. The company’s strong clinical results and strategic initiatives are likely to drive investor sentiment positively, especially if Dr. Stamler shares favorable insights during his discussions.
However, potential investors should remain vigilant regarding the inherent risks in biotechnology investments, including clinical trial uncertainties and regulatory challenges. Companies in this space are often subject to significant volatility based on trial results and market reactions to developmental milestones.
In conclusion, with its promising pipeline and strategic engagement ahead, Alterity Therapeutics presents a compelling opportunity for investors looking to capitalize on advancements in neurodegenerative disease treatments. A cautious yet optimistic approach is advised, keeping an eye on trial developments and market trends which could significantly impact share performance in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia.
At the conference, Dr. Stamler will participate in a fireside chat entitled, “Optimising Late-stage Clinical Trials to Increase the Odds,” and will also host 1-on-1 investor meetings.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors:
Tara Speranza
Head of Investor Relations and Communications
tsperanza@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ**
How does Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) plan to leverage its clinical trials in Melbourne to enhance investor confidence during the Bell Potter Healthcare Horizons Summit in March 2026?
What insights does Dr. Stamler intend to share about the successes of ATH434 at the Sorrento conference, particularly regarding its efficacy in treating Multiple System Atrophy (MSA) for Alterity Therapeutics Limited (ATHE)?
In what ways does Alterity Therapeutics Limited ATHE aim to expand its drug discovery platform in both Melbourne and San Francisco to address the challenges of neurodegenerative diseases?
What strategies will Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) employ to optimize late-stage clinical trials, as discussed during the upcoming fireside chat at the conference in March 2026?
**MWN-AI FAQ is based on asking OpenAI questions about Alterity Therapeutics Limited (NASDAQ: ATHE).
NASDAQ: ATHE
ATHE Trading
0.17% G/L:
$3.57 Last:
4,812 Volume:
$3.58 Open:
